-
More than two billion people use Facebook to share personal stories, thoughts, and updates within their networks. A recent study has now tried to gather more data on the possible health problems of users by using their language and status messages.
-
Forty percent of mobile phones used by students in health care professions are contaminated with germs. At the top of the list are Staphylococcus aureus, a problematic germ in the clinical environment and the main cause of nosocomial infections in Germany.
-
People who work longer than ten hours a day have a significantly increased risk of stroke, according to a recent study from France. In addition to office workers, physicians are also a risk group due to overtime and extra workload.
-
Every second hepatitis B infection reported in the EU is now a chronic infection. The upward trend in the number of cases observed in 2008 is thus continuing.
-
Those who use sun lotion four times or more a day enrich the blood with ingredients of the protective agent which, according to a recent toxicological study, are at least worth checking.
-
Researchers from Canada have succeeded for the first time in generating blood group 0 from blood group A using microbial enzymes.
-
A new class of antibiotics proved to be extremely effective against multi-resistant pathogens. The so-called fibupeptides inhibit the energy metabolism of bacteria by destroying the electrical potential of biomembranes.
-
The "Pasimafi" investigation did not translate into a revision of the law that Dr. Fanelli helped to draft in Italy. For many, the investigation should not halt a law that protects and guarantees access to palliative care and pain therapy for the first time in Italy.
-
The "Pasimafi" investigation brought over fifty people and ten companies to justice. At the center of this was Dr. Guido Fanelli, a medical icon of pain therapy. The scandal extended to Mundipharma, the international arm of Purdue Pharma.
-
The opioid crisis in the United States has killed more than 200,000 people. Behind this, the fingers point to the pharmaceutical giant Purdue Pharma
-
For many years, the United States has been facing a serious health crisis due to the opioid addiction epidemic. Over the last twenty years, the prescription of opioids has grown considerably, perhaps driven by pharmaceutical companies.
-
How new therapy options can be obtained from the complex pathophysiology of allergies was also the subject of EAACI 2019 in Lisbon.
-
Epigenetic changes to the genome affect cellular gene activity. Does epigenetics form the interface between environmental factors and asthmatic diseases?
-
The World Environment Day, a United Nations event, focuses this year on air pollution, an environmental problem that kills some 7 million people every year worldwide.
-
From 1 to 5 June 2019 the EAACI Congress greeted once again with a "Welcome to Lisbon"! This year's event centered primarily on precision medicine; with many innovative concepts and ideas on the future of allergology throughout the congress' numerous sessions.
-
At the end of this year's Congress of the American Society of Oncology (ASCO) in Chicago, results of the primary endpoint analysis of the CLL14 study were presented for the first time. These are results that will change current medical approaches.
-
The PD-1 inhibitor pembrolizumab (Keytruda) significantly improves the 5-year survival rates of patients with non-small cell lung cancer (NSCLC). The effect was particularly good in patients with high PD-L1 expression.
-
The non-steroidal antiandrogen ensalutamide plus standard therapy increased the 3-year survival rate in men with mHSPC to 80% compared to 72% achieved with other non-steroidal antiandrogens. This was confirmed by an interim analysis of the phase III ENZAMET study.
-
In about 50% of metastasized melanomas, a BRAF mutation is found, in these cases, targeted therapy can be applied. But immunotherapeutics have also revolutionized melanoma treatment in the last ten years.
-
For the first time, a biomarker-based therapy prolonged overall survival in premenopausal women with breast cancer. In the MONALEESA 7 Phase III study, a joint Ribociclib/endocrine therapy reduced death risk by 29%.
